Case of a Patient With Pancreatic Cancer With Sporadic Microsatellite Instability Associated With a BRAF Fusion Achieving Excellent Response to Immunotherapy

JCO Precision Oncology · 14 authors, 10 centres

AI SUMMARY

FIDELITY 100%

This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.

AGENT 01 · STRUCTURED SUMMARY

TRACE TO SOURCE

“

TL;DR

This case report details a patient with stage III, later metastatic, microsatellite instability-high (MSI-h) pancreatic cancer.

Full summary

226 CHARS

This case report details a patient with stage III, later metastatic, microsatellite instability-high (MSI-h) pancreatic cancer. After initial chemotherapy was complicated by liver abscesses, the patient received pembrolizumab.

STUDY TYPE

case_report

SPECIALTY

oncology

SUMMARISED BY

AI pipeline

FIDELITY CHECK

100% · A

ORIGINAL PAPER

PMC10309529

Case of a Patient With Pancreatic Cancer With Sporadic Microsatellite Instability Associated With a BRAF Fusion Achieving Excellent Response to Immunotherapy

JCO Precision Oncology

READ THE FULL PAPER

ABSTRACT

Abstract In this case report, we discuss a case of pancreatic cancer bearing a BRAF fusion, leading to MAPK activation, MLHph, and finally MSI.

CITATION EXPORT

Kathrin Heinrich, Laura E Fischer, Enrico N De Toni et al.. Case of a Patient With Pancreatic Cancer With Sporadic Microsatellite Instability Associated With a BRAF Fusion Achieving Excellent Response to Immunotherapy. JCO Precision Oncology. (2023). https://doi.org/10.1200/PO.22.00650

AUTHORS

14 · 10 CENTRES

Kathrin Heinrich, Laura E Fischer, Enrico N De Toni, Daniel Markwardt, Daniel Roessler, Georg Beyer, Michael Günther, Steffen Ormanns, Frederick Klauschen, Wolfgang G Kunz, Stefan Fröhling, Tilman Brummer, Volker Heinemann, C Benedikt Westphalen

1Department of Medicine III and Comprehensive Cancer Centre (CCC), LMU University Hospital Munich, Munich, Germany
2German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany
3Department of Medicine II and Comprehensive Cancer Centre (CCC), LMU University Hospital Munich, Munich, Germany
4Institute of Pathology, Ludwig Maximilians University (LMU), Munich, Germany
5Department of Radiology and Comprehensive Cancer Center (CCC Munich LMU), University Hospital, LMU Munich, Munich, Germany
6Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKTZ), Heidelberg, Germany
7DKTK, Heidelberg, Germany
8Institute of Molecular Medicine, ZBMZ, Faculty of Medicine, University of Freiburg, Freiburg, Germany
9Comprehensive Cancer Center Freiburg (CCCF), Medical Center, University of Freiburg, Freiburg, Germany
10German Cancer Consortium (DKTK), Partner Site Freiburg and German Cancer Research Center (DKFZ), Heidelberg, Germany